Ray Pillai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ray Pillai has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Aristotelis Tsirigos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
57 shared publications - Andre L. Moreira
Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
45 shared publications - Harvey I. Pass
Department of Cardiothoracic Surgery, NYU School of Medicine, New York, USA
45 shared publications - Jun-Chieh J. Tsay
NYU Langone Health 1 Division of Pulmonary and Critical Care Medicine, New York UniversityGrossman School of Medicine New York, New York
45 shared publications - Leopoldo N. Segal
Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA
37 shared publications - Daniel H. Sterman
NYU Langone Health 1 Division of Pulmonary and Critical Care Medicine, New York UniversityGrossman School of Medicine New York, New York
36 shared publications
Latest Publications
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
Lower Airway Microbiome Transcriptional and Metabolic Activities Influence Responsiveness to Immunotherapy in NSCLC
Immune checkpoint inhibitors (ICI) have transformed the treatment of advanced non–small cell lung cancer (NSCLC), yet a large proportion of patients do not respond. The lung microbiome is a key modulator of antitumor immunity; however, the functional contribution of active microbial communities and their interaction with host transcriptional programs in shaping ICI outcomes remain poorly defined. In this study, we prospectively analyzed bronchoalveolar lavage (BAL) samples from 71 patients with NSCLC prior to ICI initiation. We profiled the microbiome and host transcriptome in the BAL to look for microbial and host signatures in the lower airways associated with treatment response. We found that enrichment of the lower airway microbiome with oral commensals was associated with disease progression and worse prognosis of patients treated with ICIs. Metatranscriptomics-derived microbial clustering revealed distinct functional profiles. The microbial cluster enriched with oral commensals, which was only present among patients with poor response to ICIs, had differential regulation of pathways involved in the metabolism of short-chain fatty acids, methane, and pyruvate. This cluster also correlated with host immune pathways including upregulation of interferon signaling, neutrophil degranulation, and mitophagy, all of which could contribute to the poor response to immunotherapy. In a preclinical murine model of lung cancer with dysbiosis, inoculating lung tumor–bearing mice with oral commensals increased intratumoral neutrophils and Th17 responses and impaired ICI efficacy. Our findings support the concept that microbial communities in the lower airways influence tumor–immune interactions via defined metabolic–immune axes. Significance: Transcriptionally active lower airway microbial communities are linked clinically and preclinically to immunotherapy response in NSCLC, identifying microbial activity as a functional interface with the tumor microenvironment and a potential therapeutic target.
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
Lower Airway Microbiome Transcriptional and Metabolic Activities Influence Responsiveness to Immunotherapy in NSCLC
Immune checkpoint inhibitors (ICI) have transformed the treatment of advanced non–small cell lung cancer (NSCLC), yet a large proportion of patients do not respond. The lung microbiome is a key modulator of antitumor immunity; however, the functional contribution of active microbial communities and their interaction with host transcriptional programs in shaping ICI outcomes remain poorly defined. In this study, we prospectively analyzed bronchoalveolar lavage (BAL) samples from 71 patients with NSCLC prior to ICI initiation. We profiled the microbiome and host transcriptome in the BAL to look for microbial and host signatures in the lower airways associated with treatment response. We found that enrichment of the lower airway microbiome with oral commensals was associated with disease progression and worse prognosis of patients treated with ICIs. Metatranscriptomics-derived microbial clustering revealed distinct functional profiles. The microbial cluster enriched with oral commensals, which was only present among patients with poor response to ICIs, had differential regulation of pathways involved in the metabolism of short-chain fatty acids, methane, and pyruvate. This cluster also correlated with host immune pathways including upregulation of interferon signaling, neutrophil degranulation, and mitophagy, all of which could contribute to the poor response to immunotherapy. In a preclinical murine model of lung cancer with dysbiosis, inoculating lung tumor–bearing mice with oral commensals increased intratumoral neutrophils and Th17 responses and impaired ICI efficacy. Our findings support the concept that microbial communities in the lower airways influence tumor–immune interactions via defined metabolic–immune axes. Significance: Transcriptionally active lower airway microbial communities are linked clinically and preclinically to immunotherapy response in NSCLC, identifying microbial activity as a functional interface with the tumor microenvironment and a potential therapeutic target.
- 12 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Launching an independent research laboratory and scientific career: Tools for a rapidly changing landscape
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.
- 12 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Launching an independent research laboratory and scientific career: Tools for a rapidly changing landscape
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.
- Top Cited Papers
- 2 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6806) , 90-97
A dietary switch promotes sensory neuron–dependent cancer-associated cachexia
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.
- 2 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6806) , 90-97
Top Cited PapersA dietary switch promotes sensory neuron–dependent cancer-associated cachexia
Sickness behaviors are common in cancer-associated cachexia and affect up to half of lung cancer patients. We demonstrate that among the most common cancer mutations, loss of liver kinase B1 ( Lkb1 ) promotes the development of cachexia in preclinical models of lung cancer. In an effort to improve caloric intake with an obesogenic high-fat diet, we paradoxically observed worsened cachexia-associated sickness. We found that local production of prostaglandin E2 (PGE 2 ), rather than circulating factors, promotes sickness and that genetic, dietary, and pharmacological inhibition of tumor-derived PGE 2 suppresses sickness and cachexia. Notably, we demonstrate that lung sensory neuron abrogation prevents PGE 2 -dependent cachexia. Our study establishes localized tumor-derived signals to sensory neurons, rather than circulating factors, as drivers of cachexia and highlights a previously unknown role of the peripheral nervous system in cancer cachexia.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Gating strategy for immune cells.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Gating strategy for immune cells.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S2 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune Analysis of Lkb1 mutant lung tumors by scRNA-seq.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S2 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune Analysis of Lkb1 mutant lung tumors by scRNA-seq.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune analysis of murine Lkb1 mutant lung tumors by flow cytometry.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Immune analysis of murine Lkb1 mutant lung tumors by flow cytometry.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Loss of function mutations in Lkb1 enhance tumorigenesis.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Loss of function mutations in Lkb1 enhance tumorigenesis.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Depletion of interstitial macrophages in Lkb1 mutant lung tumors after clodronate administration increases effector T cell function.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Depletion of interstitial macrophages in Lkb1 mutant lung tumors after clodronate administration increases effector T cell function.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
LIF neutralization eliminates a dedifferentiated stem-like tumor cell state.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
LIF neutralization eliminates a dedifferentiated stem-like tumor cell state.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Lkb1 mutant tumors transcriptionally upregulate the cytokine LIF.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer
Lkb1 mutant tumors transcriptionally upregulate the cytokine LIF.